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antibodies being able to mediate immu-
nity against H. polygyrus. Combining the
authors’ findings presented here with
improved understanding of host-parasite
biology to reinfection, identification of
new immunogenic antigens and the de-
velopment of novel adjuvants should in-
crease the likelihood of effective vaccines
being generated against these debilitating
parasites.
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Plasmacytoid dendritic cells (pDCs) drive antiviral immunity through their rapid production of type I interferon
(IFN-I). In this issue, Zuniga et al. (2008) report that both acute and persistent viral infections dramatically
decrease pDC numbers and impair their capacity to produce IFN-I, leading to an enhanced susceptibility
to opportunistic viruses.Chronic viral infections signify the failure
of the host’s immune system to eradicate
the virus or to efficiently control its replica-
tion. It is well established that impairment
of adaptive immunity specific to the virus,
especially a functional paralysis of cyto-
toxic CD8 T lymphocytes driven in part
by high interleukin-10 (IL-10) production,
is involved (Brooks et al., 2006). However,
a more generalized state of immunodefi-
ciency often arises during chronic viral
infections, which is frequently associated
with enhanced susceptibility to unrelated
opportunistic pathogens, including other
viruses. This phenomenon can lead to
life-threatening conditions as in the case
of infections with human immunodefi-
ciency virus type-I (HIV-I), which induces
a progressive and general weakening of
adaptive CD4 T cell-dependent immune
defenses against a number of opportunis-tic agents during the asymptomatic phase
of the infection. This ultimately results in
complete loss of immune control over
these secondary pathogens and death.
However, whether innate antiviral immune
defenses may be compromised during
chronic infections with HIV-I or other
viruses, and to which extent this could
contribute to enhanced susceptibility to
opportunistic agents in vivo is not well
documented. In the current issue of Cell
Host & Microbe, Zuniga et al., 2008 report
a well-rounded and captivating study to
address this question.
Innate immunity against viral infections
is characterized by rapid and robust type
I interferon (IFN-I) production. IFN-I dis-
plays a wide range of biological properties
crucial for the global orchestration of anti-
viral immunity (Garcia-Sastre and Biron,
2006). IFN-I exerts direct, potent, antiviralCell Host & Microbe 4effects. It also promotes the cytotoxic
functions of innate NK cells and adaptive
CD8 T lymphocytes, either directly or
through the licensing of conventional den-
dritic cells. Several in vitro studies have
described that many viruses can impair
IFN-I production by infected cells. Infec-
tions with certain viruses, including
HIV-I, have even been shown to generally
compromise the ability of the host’s
leukocytes to produce IFN-I upon in vitro
restimulation with other viruses or stimuli.
The present work provides proof that
a drastic decrease of IFN-I production
upon secondary viral infections does oc-
cur in vivo, under physiological conditions
of a primary infection with lymphocytic
choriomeningitis virus (LCMV) or murine
cytomegalovirus (MCMV) in their natural
host, the mouse. This impairment of IFN-I
responses is observed against a variety, October 16, 2008 ª2008 Elsevier Inc. 305
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PreviewsFigure 1. Impact of Primary Viral Infections on Immune Responses to Secondary Challenges
(A) Both acute and chronic primary viral infections inhibit the host’s innate and adaptive immune
responses to heterologous challenges. Acute primary viral infections impair host’s immune responses
to secondary virus in terms of pDC numbers, IFN-I production, T and B activation and NK cell functions
between days 5 and 9 (blue). Chronic viral infections decrease pDC numbers, IFN-I production, and NK
cell functions leading to enhanced susceptibility to opportunistic infections starting at day 5 for an ex-
tended period of time, until after day 40 (red).
(B) Potential mechanisms for the inhibition of IFN-I production during heterologous challenges in the
course of a primary viral infection. Virus infections or administration of synthetic TLR-3, -7, or -9 ligands
fail to induce high systemic levels of IFN-I upon heterologous challenges during a primary viral infection,
whereas a TLR-4 stimulation leads to enhanced IFN-I production. Different mechanisms could be pro-
posed to explain the TLR-IFN-I inhibition. First, it could be a deficiency in the endocytosis or intracellular
trafficking of TLR ligands. Second, it could be an alteration of the expression or the intracellular trafficking
of endosomal TLRs after primary viral infections. Third, an inhibition of the activation of IRF-3 or IRF-7 may
occur consecutively to the induction of inhibitory signals, which could be delivered for example by the TAM
tyrosine kinases or by the glucorticoid response.of secondary, heterologous, viral-type
challenges, including MCMV, LCMV,
VSV, or synthetic ligands for Toll-like
receptor (TLR) -3, -7, and -9 which are
innate immune recognition receptors that
sense viral nucleotides. These results are
consistent with those recently published
independently by another team (Alsharifi
et al., 2006). However, the study by Zuniga306 Cell Host & Microbe 4, October 16, 2008et al. (2008) presents a number of other
striking observations and brings definitive
advances in deciphering the underlying
mechanisms.
Zuniga and coworkers demonstrate
that the paralysis of innate antiviral
immune defenses induced by a primary
viral challenge is transient in the case of
an acute infection but long lasting in theª2008 Elsevier Inc.case of a chronic infection (Figure 1A).
Moreover, they demonstrate a striking
correlation between this paralysis and
the development of quantitative and qual-
itative defects in plasmacytoid dendritic
cells (pDCs). pDCs are believed to be
key players in antiviral defense due to
their unique capacity to rapidly detect vi-
ral particles or infected cells and respond
by immediately producing high levels of
all subtypes of IFN-I, without the require-
ment for viral replication within the pDCs
themselves. pDC sensing of viral infection
occurs mainly through the engagement of
TLR-7 or -9 by nucleic acids, in special-
ized endosomes, which leads to the acti-
vation of interferon regulatory factor (IRF)
-3 and -7, the major transcription factors
driving IFN-I production (Gilliet et al.,
2008) The numbers of pDCs and their
ability to produce IFN-I are drastically
reduced early after an acute viral infection
and permanently during a chronic viral in-
fection (Zuniga et al., 2008). In contrast,
and remarkably, pDC production of other
innate cytokines or chemokines does not
seem significantly affected. The identifi-
cation of pDC as a major target cell type
for the general immunosuppression
induced by viral infection, and the obser-
vation of differential modulation of distinct
pDC functions by viral infections paves
the way for deciphering the underlying
molecular mechanisms.
The authors have made multiple at-
tempts at identifying the mechanisms
dampening pDC IFN-I production to sec-
ondary heterologous challenges during
a primary viral infection. They have exam-
ined pathways known to compromise
adaptive immunity in the same model,
for example the role of IL-10 (Brooks
et al., 2006), which can also inhibit pDC
IFN-I production in vitro (Contractor
et al., 2007). They have also investigated
the involvement of T lymphocytes as a
major source of TGF-b, another immuno-
regulatory cytokine known to impair pDC
IFN-I production in vitro (Contractor
et al., 2007) and to be produced during
chronic LCMV infection. They also evalu-
ated IFN-I itself, because it can terminate
its own production through a negative
feedback loop that involves the upregula-
tion and activation of the TAM protein
tyrosine kinases on pDCs and the down-
stream induction of the suppressors of
cytokine signaling (SOCS)-1 and -3
(Rothlin et al., 2007). However, and
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seems to individually bear a significant
contribution to the induction of pDC paral-
ysis during viral infections. It is possible
that the function of these pathways is
largely redundant such that their com-
bined inactivation would be required to
restore pDC responsiveness. However, it
is also possible that other, yet unexplored,
mechanisms are involved.
Several critical steps are involved in the
production of IFN-I by pDCs in response
to viral challenges, which could be altered
early after acute viral infections or perma-
nently in the case of chronic viral infec-
tions (Figure 1B). pDCs need to engulf
free viral particles or apoptotic bodies
from infected cells and direct their traf-
ficking to specialized IRF-7-associated
endosomes, which are distinct from
endosomes where IL-12 production is ini-
tiated in an IRF-5-dependant manner (Gil-
liet et al., 2008). Since only IFN-I but not
IL-12 production by pDCs seems affected
in the reported study, it is possible that the
trafficking of endocytosed viral compo-
nents toward IRF-7-associated endo-
somes is specifically altered after a pri-
mary viral infection. Another explanation
could be an alteration of the expression
or intracellular trafficking of the TLRs
themselves, as reported in another study
(Schroeder et al., 2005). The activity of
components downstream of the TLRs,
which are specifically involved in the
induction of IFN-I as opposed to IL-12,
could be altered—e.g., the availability or
activation of IRF-3 or IRF-7. This may re-
sult from other inhibitory signals than
those driven by the TAM tyrosine kinases,
such as the pDC response to glucocor-
ticoids. Indeed, glucocorticoids have
been demonstrated to be induced during
viral infection in response to the direct
stimulation of the adrenal glands by IL-6and to dampen the production of proin-
flammatory cytokines (Ruzek et al.,
1999). Moreover, steroid hormones can
dampen IFN-I production through the in-
hibition of IRF-3 and IRF-7 activation
(O’Neill, 2008). It would therefore be very
interesting to test the impact of adrenal-
ectomy on pDC responses to secon-
dary challenges during LCMV infection.
However, as the authors underline, the
mechanisms modulating pDC responses
to secondary challenges during primary
viral infections are likely to be highly com-
plex and to involve different pathways that
could be partly redundant.
Finally, the authors pinpoint a significant
difference in the consequences of damp-
ening pDC IFN-I production during
primary viral infections depending on the
nature of the heterologous virus used for
the secondary challenge. Indeed, al-
though a drastic decrease in the systemic
levels of IFN-I production is observed in
response to all secondary viral infections,
this leads to a significant impairment in
the ability to control viral replication only
in the case where MCMV is used as a chal-
lenging agent, and not for LCMV or VSV.
This is likely to be relevant to the natural
history of opportunistic infections, as se-
vere complications due to uncontrolled
reactivation of herpes viruses including
human CMV, HHV8, or EBV are most
commonly encountered in patients with
advanced HIV-I infection. This may result
from the impairment of both the direct an-
tiviral activity of pDCs and their priming
role for NK cell activation as demon-
strated in the present study.
In summary, in this issue of Cell Host &
Microbe, Zuniga and colleagues demon-
strate that systemic production of IFN-I
by pDCs in response to a secondary chal-
lenge is severely reduced after a primary
viral infection in mice. This occurs tran-Cell Host & Microbe 4siently in the case of an acute infection
but permanently during a chronic infec-
tion, and leads to enhanced susceptibility
to opportunistic agents such as herpes
viruses. The identification of the underly-
ing mechanisms will be an interesting
challenge to address in future studies in
order to be able to design novel therap-
eutic strategies to fight opportunistic
infections.
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